Compare $BCRX vs $IMNM | Chartloom

Compare

$BCRX vs $IMNM

BioCryst Pharmaceuticals Inc · Immunome Inc

BCRX

BioCryst Pharmaceuticals Inc

IMNM

Immunome Inc

Compare $BCRX vs $IMNM

Comparing BioCryst Pharmaceuticals Inc and Immunome Inc

BCRXBioCryst Pharmaceuticals Inc

IMNMImmunome Inc

BCRXBioCryst Pharmaceuticals Inc

Market cap

$2.17B

P/E (TTM)

—

Forward P/E (NTM)

16.67x

Forward P/S (NTM)

3.13x

Rev growth (TTM)

68.7%

YTD performance

14.0%

52W performance

17.4%

FCF yield

17.9%

IMNMImmunome Inc

Market cap

$2.21B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

127.50x

Rev growth (TTM)

-100.0%

YTD performance

-6.1%

52W performance

39.5%

FCF yield

-10.3%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

BCRX

IMNM

Detailed metrics comparison

BCRX

BioCryst Pharmaceuticals Inc

IMNM

Immunome Inc

Market Cap

BCRX$2.17B

IMNM$2.21B

Enterprise Value

BCRX$2.84B

IMNM$2.00B

Price

BCRX$8.55

IMNM$19.55

P/E Ratio

BCRXN/A

IMNMN/A

P/S Ratio

BCRX2.31x

IMNM188.56x

EV/Sales

BCRX3.02x

IMNM171.27x

EV/EBITDA

BCRX6.85x

IMNM0.00x

P/B Ratio

BCRX62.13x

IMNM4.52x

P/FCF Ratio

BCRX5.59x

IMNMN/A

EV/FCF

BCRX7.32x

IMNM-8.75x

PEG Ratio

BCRXN/A

IMNMN/A

Forward P/E (NTM)

BCRX16.67x

IMNMN/A

Forward P/S (NTM)

BCRX3.13x

IMNM127.50x

Revenue (TTM)

BCRX$941M

IMNM$0

Revenue Growth (YoY)

BCRX68.7%

IMNM-100.0%

Forward Rev Growth

BCRX3.9%

IMNM15247.2%

Gross Margin (TTM)

BCRX97.8%

IMNM0.0%

Operating Margin (TTM)

BCRX0.0%

IMNM0.0%

EBITDA Margin (TTM)

BCRX41.1%

IMNM0.0%

Net Margin (TTM)

BCRX-40.9%

IMNM0.0%

FCF Margin (TTM)

BCRX41.3%

IMNMN/A

Net Income (TTM)

BCRX$-385M

IMNM$-254M

FCF (TTM)

BCRX$388M

IMNM$-228M

EPS (TTM)

BCRX-$1.45

IMNM-$2.25

ROE (TTM)

BCRX-32882.0%

IMNM-5056.0%

ROA (TTM)

BCRX-7758.0%

IMNM-4693.0%

ROIC (TTM)

BCRX-10666.0%

IMNM-5056.0%

Cash

BCRX$155M

IMNM$218M

Debt

BCRX$824M

IMNM$0

Net Cash/Debt

BCRX$-669M

IMNM$218M

Current Ratio (TTM)

BCRX2.32x

IMNM15.08x

Quick Ratio (TTM)

BCRX2.22x

IMNM14.56x

Debt/Equity (TTM)

BCRX2.26x

IMNM0.00x

Debt/Assets (TTM)

BCRX0.0%

IMNM0.0%

Interest Coverage (TTM)

BCRXN/A

IMNMN/A

Net Debt/EBITDA (TTM)

BCRX0.00x

IMNM0.00x

Beta

BCRX0.54

IMNM2.65

52W Performance

BCRX17.4%

IMNM39.5%

YTD Performance

BCRX14.0%

IMNM-6.1%

% from 52W High

BCRX-23.8%

IMNM-35.0%

% from 52W Low

BCRX42.5%

IMNM44.9%

Asset Turnover (TTM)

BCRX1.90x

IMNM0.04x

FCF Yield (TTM)

BCRX17.9%

IMNM-10.3%

Earnings Yield (TTM)

BCRX-17.7%

IMNM-11.5%

Dividend Yield (TTM)

BCRXN/A

IMNMN/A

Rule of 40

BCRX110.0

IMNM-100.0

EV/GP/RG

BCRX0.74

IMNMN/A

Ticker research

View BCRX research View IMNM research

Metric	BCRX BioCryst Pharmaceuticals Inc	IMNM Immunome Inc
Market & Valuation
Market Cap	$2.17B	$2.21B
Enterprise Value	$2.84B	$2.00B
Price	$8.55	$19.55
P/E Ratio	N/A	N/A
P/S Ratio	2.31x	188.56x
EV/Sales	3.02x	171.27x
EV/EBITDA	6.85x	0.00x
P/B Ratio	62.13x	4.52x
P/FCF Ratio	5.59x	N/A
EV/FCF	7.32x	-8.75x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	16.67x	N/A
Forward P/S (NTM)	3.13x	127.50x
Revenue & Growth
Revenue (TTM)	$941M	$0
Revenue Growth (YoY)	68.7%	-100.0%
Forward Rev Growth	3.9%	15247.2%
Profitability
Gross Margin (TTM)	97.8%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	41.1%	0.0%
Net Margin (TTM)	-40.9%	0.0%
FCF Margin (TTM)	41.3%	N/A
Net Income (TTM)	$-385M	$-254M
FCF (TTM)	$388M	$-228M
EPS (TTM)	-$1.45	-$2.25
ROE (TTM)	-32882.0%	-5056.0%
ROA (TTM)	-7758.0%	-4693.0%
ROIC (TTM)	-10666.0%	-5056.0%
Financial Health
Cash	$155M	$218M
Debt	$824M	$0
Net Cash/Debt	$-669M	$218M
Current Ratio (TTM)	2.32x	15.08x
Quick Ratio (TTM)	2.22x	14.56x
Debt/Equity (TTM)	2.26x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.54	2.65
52W Performance	17.4%	39.5%
YTD Performance	14.0%	-6.1%
% from 52W High	-23.8%	-35.0%
% from 52W Low	42.5%	44.9%
Efficiency & Yields
Asset Turnover (TTM)	1.90x	0.04x
FCF Yield (TTM)	17.9%	-10.3%
Earnings Yield (TTM)	-17.7%	-11.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	110.0	-100.0
EV/GP/RG	0.74	N/A
Ticker research	View BCRX research	View IMNM research

Valuation

P/S Ratio

BCRX

2.31x

IMNM

188.56x

EV/FCF

IMNM

-8.75x

BCRX

7.32x

Growth & revenue

Revenue Growth TTM

BCRX

68.7%

IMNM

-100.0%

Forward Revenue Growth

IMNM

15247.2%

BCRX

3.9%

Profitability & performance

Gross Margin

BCRX

97.8%

IMNM

0.0%

ROE

IMNM

-5056.0%

BCRX

-32882.0%

FCF Yield %

BCRX

17.9%

IMNM

-10.3%

52-Week Performance

IMNM

39.5%

BCRX

17.4%

Detailed metrics comparison

BCRX

BioCryst Pharmaceuticals Inc

IMNM

Immunome Inc

Market Cap

BCRX$2.17B

IMNM$2.21B

Enterprise Value

BCRX$2.84B

IMNM$2.00B

Price

BCRX$8.55

IMNM$19.55

P/E Ratio

BCRXN/A

IMNMN/A

P/S Ratio

BCRX2.31x

IMNM188.56x

EV/Sales

BCRX3.02x

IMNM171.27x

EV/EBITDA

BCRX6.85x

IMNM0.00x

P/B Ratio

BCRX62.13x

IMNM4.52x

P/FCF Ratio

BCRX5.59x

IMNMN/A

EV/FCF

BCRX7.32x

IMNM-8.75x

PEG Ratio

BCRXN/A

IMNMN/A

Forward P/E (NTM)

BCRX16.67x

IMNMN/A

Forward P/S (NTM)

BCRX3.13x

IMNM127.50x

Revenue (TTM)

BCRX$941M

IMNM$0

Revenue Growth (YoY)

BCRX68.7%

IMNM-100.0%

Forward Rev Growth

BCRX3.9%

IMNM15247.2%

Gross Margin (TTM)

BCRX97.8%

IMNM0.0%

Operating Margin (TTM)

BCRX0.0%

IMNM0.0%

EBITDA Margin (TTM)

BCRX41.1%

IMNM0.0%

Net Margin (TTM)

BCRX-40.9%

IMNM0.0%

FCF Margin (TTM)

BCRX41.3%

IMNMN/A

Net Income (TTM)

BCRX$-385M

IMNM$-254M

FCF (TTM)

BCRX$388M

IMNM$-228M

EPS (TTM)

BCRX-$1.45

IMNM-$2.25

ROE (TTM)

BCRX-32882.0%

IMNM-5056.0%

ROA (TTM)

BCRX-7758.0%

IMNM-4693.0%

ROIC (TTM)

BCRX-10666.0%

IMNM-5056.0%

Cash

BCRX$155M

IMNM$218M

Debt

BCRX$824M

IMNM$0

Net Cash/Debt

BCRX$-669M

IMNM$218M

Current Ratio (TTM)

BCRX2.32x

IMNM15.08x

Quick Ratio (TTM)

BCRX2.22x

IMNM14.56x

Debt/Equity (TTM)

BCRX2.26x

IMNM0.00x

Debt/Assets (TTM)

BCRX0.0%

IMNM0.0%

Interest Coverage (TTM)

BCRXN/A

IMNMN/A

Net Debt/EBITDA (TTM)

BCRX0.00x

IMNM0.00x

Beta

BCRX0.54

IMNM2.65

52W Performance

BCRX17.4%

IMNM39.5%

YTD Performance

BCRX14.0%

IMNM-6.1%

% from 52W High

BCRX-23.8%

IMNM-35.0%

% from 52W Low

BCRX42.5%

IMNM44.9%

Asset Turnover (TTM)

BCRX1.90x

IMNM0.04x

FCF Yield (TTM)

BCRX17.9%

IMNM-10.3%

Earnings Yield (TTM)

BCRX-17.7%

IMNM-11.5%

Dividend Yield (TTM)

BCRXN/A

IMNMN/A

Rule of 40

BCRX110.0

IMNM-100.0

EV/GP/RG

BCRX0.74

IMNMN/A

Ticker research

View BCRX research View IMNM research

Metric	BCRX BioCryst Pharmaceuticals Inc	IMNM Immunome Inc
Market & Valuation
Market Cap	$2.17B	$2.21B
Enterprise Value	$2.84B	$2.00B
Price	$8.55	$19.55
P/E Ratio	N/A	N/A
P/S Ratio	2.31x	188.56x
EV/Sales	3.02x	171.27x
EV/EBITDA	6.85x	0.00x
P/B Ratio	62.13x	4.52x
P/FCF Ratio	5.59x	N/A
EV/FCF	7.32x	-8.75x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	16.67x	N/A
Forward P/S (NTM)	3.13x	127.50x
Revenue & Growth
Revenue (TTM)	$941M	$0
Revenue Growth (YoY)	68.7%	-100.0%
Forward Rev Growth	3.9%	15247.2%
Profitability
Gross Margin (TTM)	97.8%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	41.1%	0.0%
Net Margin (TTM)	-40.9%	0.0%
FCF Margin (TTM)	41.3%	N/A
Net Income (TTM)	$-385M	$-254M
FCF (TTM)	$388M	$-228M
EPS (TTM)	-$1.45	-$2.25
ROE (TTM)	-32882.0%	-5056.0%
ROA (TTM)	-7758.0%	-4693.0%
ROIC (TTM)	-10666.0%	-5056.0%
Financial Health
Cash	$155M	$218M
Debt	$824M	$0
Net Cash/Debt	$-669M	$218M
Current Ratio (TTM)	2.32x	15.08x
Quick Ratio (TTM)	2.22x	14.56x
Debt/Equity (TTM)	2.26x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.54	2.65
52W Performance	17.4%	39.5%
YTD Performance	14.0%	-6.1%
% from 52W High	-23.8%	-35.0%
% from 52W Low	42.5%	44.9%
Efficiency & Yields
Asset Turnover (TTM)	1.90x	0.04x
FCF Yield (TTM)	17.9%	-10.3%
Earnings Yield (TTM)	-17.7%	-11.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	110.0	-100.0
EV/GP/RG	0.74	N/A
Ticker research	View BCRX research	View IMNM research